| Size | Price | Stock | Qty |
|---|---|---|---|
| 250g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
O-Benzylhydroxylamine hydrochloride does not have a specific primary biological target, as it functions primarily as a synthetic reagent rather than a direct pharmacological agent. However, its derivatives, such as hydroxamic acids, are known to be potent inhibitors of enzymes like histone deacetylases (HDACs) and matrix metalloproteinases. HDACs are involved in the regulation of gene expression through histone deacetylation, and their inhibitors are being investigated for the treatment of cancer and neurological disorders. Matrix metalloproteinases are involved in the degradation of extracellular matrix, and their inhibitors are being explored for the treatment of inflammatory diseases and cancer. The compound is also used in the synthesis of β-lactam inhibitor precursors and fluoroquinolone derivatives with antibiotic activity, suggesting that its derivatives may target bacterial enzymes or cellular processes.
|
|---|---|
| ln Vitro |
O-Benzylhydroxylamine is a necessary component. Antibiotic-active derivatives of fluoroquinolones and precursors of β-lactam inhibitors have been synthesized using it.
In vitro, O-benzylhydroxylamine hydrochloride is used as a building block in the synthesis of β-lactam inhibitor precursors and fluoroquinolone derivatives with antibiotic activity. It reacts with aldehydes and ketones to form stable O-benzyl oximes. Hydroxamic acids synthesized from this compound are potent inhibitors of enzymes like HDACs and matrix metalloproteinases. The compound is a necessary component for the synthesis of antibiotic-active derivatives of fluoroquinolones. In medicinal chemistry, it serves as a versatile building block for constructing biologically active molecules. Its ability to form oximes makes it valuable for the protection and derivatization of carbonyl compounds in organic synthesis. |
| ln Vivo |
In vivo activity is mediated through the derivatives of O-benzylhydroxylamine hydrochloride rather than the parent compound itself. For example, fluoroquinolone derivatives with antibiotic activity are evaluated in animal models of bacterial infection. HDAC inhibitors synthesized from this compound are evaluated in animal models of cancer and neurological disorders. Matrix metalloproteinase inhibitors are evaluated in animal models of inflammatory diseases and cancer. However, specific in vivo studies on the parent compound are not documented, as it is a synthetic intermediate rather than a pharmacological agent.
|
| Enzyme Assay |
Cell-free assays involving O-benzylhydroxylamine hydrochloride are focused on its use as a chemical reagent. Standard protocols for oxime formation involve mixing the compound with an aldehyde or ketone in an appropriate solvent with a base such as pyridine at room temperature. The reaction progress is monitored by TLC, and the product is purified by recrystallization or column chromatography. For the synthesis of hydroxamic acids, the compound is used as a starting material in multi-step synthetic routes. The compound's reactivity can be studied using various analytical techniques, including NMR spectroscopy and mass spectrometry. Its use in the synthesis of β-lactam inhibitor precursors and fluoroquinolone derivatives involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not performed with the parent compound O-benzylhydroxylamine hydrochloride. Instead, its derivatives, such as fluoroquinolone antibiotics and HDAC inhibitors, are evaluated in cell-based systems. For fluoroquinolone antibiotics, antimicrobial susceptibility tests are performed using bacterial cultures. For HDAC inhibitors, cancer cell lines are treated with the derivatives, and cell viability, proliferation, and histone acetylation are measured. For matrix metalloproteinase inhibitors, cell lines are treated with the derivatives, and enzyme activity and extracellular matrix degradation are measured. The parent compound itself is not used as a test article in cell-based experiments.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound O-benzylhydroxylamine hydrochloride. Its derivatives, such as fluoroquinolone antibiotics and HDAC inhibitors, are evaluated in animal models. For fluoroquinolone antibiotics, animal models of bacterial infection are used, and bacterial clearance and survival rates are assessed. For HDAC inhibitors, animal models of cancer and neurological disorders are used, and tumor growth or behavioral parameters are assessed. For matrix metalloproteinase inhibitors, animal models of inflammatory diseases are used, and inflammatory markers are measured. The parent compound itself is not administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for the parent compound O-benzylhydroxylamine hydrochloride are not available. As a small polar molecule with a molecular weight of 159.62 g/mol, it is expected to have moderate bioavailability if administered, but it is not intended for therapeutic use. Comprehensive pharmacokinetic studies have not been performed, as the compound is not intended for systemic administration. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for O-benzylhydroxylamine hydrochloride are limited. Standard safety precautions for handling hydroxylamines and hydrochloride salts apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| References |
[1]. Bellettini, JR, and Miller, MJA short synthesis of an important precursor to a new class of bicyclic β-lactamase inhibitorsTetrahedron Lett.38(2)167-168(1997)
[2]. Asadipour, A., Moshafi, MH, Khosravani, L., et al.N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluationDaru.26(2)199-207(2018) |
| Additional Infomation |
O-Benzylhydroxylamine hydrochloride is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a building block used in the synthesis of β-lactam inhibitor precursors and fluoroquinolone derivatives with antibiotic activity. It reacts with aldehydes and ketones to form stable O-benzyl oximes. Hydroxamic acids synthesized from this compound are potent inhibitors of enzymes like HDACs and matrix metalloproteinases. The compound is a necessary component for the synthesis of antibiotic-active derivatives of fluoroquinolones. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. It is supplied with a purity of ≥99.9% and should be stored in a cool, dry place.
|
| Molecular Formula |
C7H10CLNO
|
|---|---|
| Molecular Weight |
159.61
|
| Exact Mass |
159.045
|
| CAS # |
2687-43-6
|
| Related CAS # |
622-33-3 (Parent)
|
| PubChem CID |
102312
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
237.5ºC at 760 mmHg
|
| Melting Point |
238 °C (subl.)(lit.)
|
| Flash Point |
113.1ºC
|
| Vapour Pressure |
0.00923mmHg at 25°C
|
| LogP |
2.579
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
69.3
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.C(ON)C1C=CC=CC=1
|
| InChi Key |
HYDZPXNVHXJHBG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO.ClH/c8-9-6-7-4-2-1-3-5-7;/h1-5H,6,8H2;1H
|
| Chemical Name |
O-benzylhydroxylamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2653 mL | 31.3264 mL | 62.6527 mL | |
| 5 mM | 1.2531 mL | 6.2653 mL | 12.5305 mL | |
| 10 mM | 0.6265 mL | 3.1326 mL | 6.2653 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
